| Literature DB >> 30658661 |
Anne Richter1, Florian Exner2, Klaus Bratengeier2, Bülent Polat2, Michael Flentje2, Stefan Weick2.
Abstract
BACKGROUND: The purpose of this study was to compare automatically generated VMAT plans to find the superior beam configurations for Pinnacle3 Auto-Planning and share "best practices".Entities:
Keywords: Auto-planning; Double arc; Full arc; Partial arc; Plan comparison; Single arc; VMAT
Mesh:
Year: 2019 PMID: 30658661 PMCID: PMC6339276 DOI: 10.1186/s13014-019-1211-6
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Overview of patient population
| Case | Disease type | Treatment concept | Fractionation Scheme Dose D95 in Gy | Fractions | Side location |
|---|---|---|---|---|---|
| 1 | SCC, Hypopharynx | Primary RCT | 59,4/66/69,3 | 33 | bilateral |
| 2 | SCC, Oral cavity | Adjuvant RT | 54/66 | 30 | bilateral |
| 3 | SCC, Oropharynx | Adjuvant RT | 54/66 | 30 | bilateral |
| 4 | SCC, Oral cavity | Adjuvant RCT | 54/66 | 30 | bilateral |
| 5 | SCC, Oropharynx | Adjuvant RCT | 60/66 | 30 | bilateral |
| 6 | SCC, Oral cavity | Adjuvant RCT | 54/66 | 30 | bilateral |
| 7 | SCC, Oropharynx | Adjuvant RCT | 54/66 | 30 | bilateral |
| 8 | SCC, Oral cavity | Adjuvant RCT | 54/66 | 30 | bilateral |
| 9 | CUP, Oropharynx | Adjuvant RT | 52,7/65,1 | 31 | bilateral |
| 10 | SCC, Oral cavity | Adjuvant RCT | 54/66 | 30 | bilateral |
| 11 | SCC, Oropharynx | Adjuvant RT | 54/66 | 30 | unilateral |
| 12 | SCC, Oropharynx | Adjuvant RCT | 54/66 | 30 | unilateral |
| 13 | SCC, Oropharynx | Adjuvant RCT | 60/66 | 30 | unilateral |
| 14 | Undifferentiated orbital cancer | Adjuvant RT | 60/66 | 30 | unilateral |
| 15 | SCC, external auditory canal | Adjuvant RT | 54/66 | 30 | unilateral |
| 16 | SCC, occipital skin | Adjuvant RT | 54/66 | 30 | unilateral |
| 17 | SCC, Oropharynx | Adjuvant RCT | 54/66 | 30 | unilateral |
| 18 | SCC, Nasal cavity | Adjuvant RT | 54/66 | 30 | unilateral |
| 19 | SCC, Oral cavity | Adjuvant RCT | 60/66 | 30 | unilateral |
| 20 | NHL of the parotid gland | Adjuvant RT | 40 | 20 | unilateral |
All except one patient (Case #20) were treated with a simultaneously integrated boost technique with 2–3 dose levels
CUP Cancer of Unknown Primacy, RCT Radio-Chemo Therapy, RT Radiotherapy, SCC Squamous Cell Carcinoma
Disease type, treatment concept, fractionation scheme and tumor side location are described for all 20 patients
Overview of beam configurations and list of comparisons. Varying beam configurations are displayed on the left part: Single, double and two single arc types, full and partial arc length and different collimator positions were defined and used for comparison. The corresponding list of comparison between the different beam configurations is displayed on the right part
| Name | Arc type | Arc length | Collimator position | List of comparisons |
|---|---|---|---|---|
| V1C15 | Single arc | Full | 15° | 1. V2C15 vs. V1 C15 |
| V2C15 | Double arc | Full | 15° | 2. V2C15 vs. 2V1C15 |
| V2C15_Part | Double arc | Partial | 15° | 3. V2C15 vs. V2C15_Part |
| V2C15 | Double arc | Full | 15° | 4. V2C15 vs. V2C40 |
| V2C40 | Double arc | Full | 40° | 5. V2C15 vs. V2C60 |
| V2C60 | Double arc | Full | 60° | 6. V2C15 vs. 2V1C15_60 |
| 2V1C15 | Two single arcs | Full | 15°, 15° | 7. V2C15 vs. 2V1C15_345 |
| 2V1C15_60 | Two single arcs | Full | 15°, 60° | 8. 2V1C15_60 vs. 2V1C15_345 |
| 2V1C15_345 | Two single arcs | Full | 15°, 345° |
Note: Single arc with collimator 15° (V1C15), Full double arc with collimator 15° (V2C15), partial arcs (V2C15_Part), Two single arcs with different collimator positions (A and B) (2V1CA_CB), Partial arc with collimator 15° (V2C15_Part)
Example of evaluation parameter set for case #1
| Structure | DVH Parameter | Dose Limit in relation to D95 | Absolute Dose | |
|---|---|---|---|---|
| PTV1 | D95 | ± 2% | 69,30 | |
| D98 | > | 0,95 D95 | 65,8 | |
| Dmin | > | 0,9 D95 | 62,4 | |
| STD | < | 3,3% | 2,3 | |
| PTV2 | D95 | ± 2% | 66,00 | |
| D98 | > | 0,95 D95 | 62,7 | |
| Dmin | > | 0,9 D95 | 59,4 | |
| STD | < | 3,3% | 2,2 | |
| PTV3 | D95 | > | ± 2% | 59,40 |
| D98 | > | 0,95 D95 | 56,4 | |
| Dmin | < | 0,9 D95 | 53,5 | |
| STD | < | 3,3% | 2,0 | |
| SpinalCanal | D 1cm3 | < | 45 | |
| BrainStem | D 1cm3 | < | 45 | |
| Left Parotid | D66 | < | 20 | |
| Dmean | < | 26 | ||
| Right Parotid | D66 | < | 20 | |
| Dmean | < | 26 | ||
| Larynx | D05 | < | 69 | |
| D05 | < | 45 | ||
| Mandible | D05 | < | 69 | |
| D10 | < | 60 | ||
| D50 | < | 52 | ||
| Neck | Dmax | < | 40 | |
| Left Lens | D05 | < | 9 | |
| Right Lens | D05 | < | 9 | |
| Left OpticNerve | D05 | < | 50 | |
| Right OpticNerve | D05 | < | 50 | |
| Chiasm | D05 | < | 50 | |
| Pituitary | D05 | < | 50 | |
| Left InnerEar | D05 | < | 30 | |
| Right InnerEar | D05 | < | 30 | |
| Outline | DMax | < | 1,15 D95 | 79,7 |
Definition of an evaluation parameter set for an integrated boost technique with three dose levels (PTV1, PTV2, PTV3). Requirements for target coverage and dose homogeneity are described by DVH parameters, relative and absolute dose limits scaled according to the prescription dose D95 of each PTV (top part). DVH parameters and absolute dose limits are listed for organs at risk (bottom part)
D Minimum Dose, D Maximum Dose, D Mean Dose, STD Standard deviation, D Volume X is covered by the dose value, PTV Planning target volume
Rules for the scoring method
| Requirement met | Deviation (A vs. B) | Scoring | |
|---|---|---|---|
| Plan A | Plan B | ||
| true | true | ≥ 1% | A or B (closer) |
| < 1% | tie | ||
| false | false | ≥ 1% | A or B (closer) |
| < 1% | tie | ||
| true | false | A | |
| false | true | B | |
If the deviation was less than 1%, no trial achieved the score (tie). If both trials failed the requirement, the better plan achieved the score. If a plan fulfilled the requirement (true), this plan achieved the score
If both plans met the requirement and the deviation was more than 1%, the better plan achieved the score
Fig. 1Flow chart of COV method
Summary of plan quality
| Comparison of techniques | p-value | Superior technique | ||
|---|---|---|---|---|
| COV based | Scoring based | |||
| 1 | V2C15 vs. V1 C15 | 0,00009 * | 0,00009 * | V2C15 |
| 2 | V2C15 vs. 2V1C15 | 0,00012 * | 0,00054 * | V2C15 |
| 3 | V2C15 vs. V2C15_Part | 0,0047 * | 0,036 * | V2C15 |
| 4 | V2C15 vs. V2C40 | 0,12 | 0,78 | |
| 5 | V2C15 vs. V2C60 | 0,00078 * | 0,0083 * | V2C15 |
| 6 | V2C15 vs. 2V1C15_60 | 0,43 | 0,39 | |
| 7 | V2C15 vs. 2V1C15_345 | 0,01 * | 0,041 * | V2C15 |
| 8 | 2V1C15_60 vs. 2V1C15_345 | 0,0051 * | 0,22 | 2V1C15_60 |
Techniques with different beam configurations were compared with regard to plan quality using COV and scoring method. The p-value of the Wilcoxon signed rank test shows if the techniques differed significantly and the superior technique is listed
*Significant differences are marked (p < 0,05)
Fig. 2Comparison of plan quality with the COV method. Plan quality was evaluated and COV ratios for comparison #1–3 are shown. Plan quality of V2C15 is superior if the first COV ratio is below 1 (open circles) and the second COV ratio is greater than 1 (filled circles). a COV ratios for comparison #1: single arc (V1C15) and double arc (V2C15) for 20 patients. b COV ratios for two single arcs with collimator rotation (2V1C15) and double arc (V2C15) for 20 patients. c COV ratios for full (V2C15) and partial arcs (V2C15_Part) for 10 patients with unilateral target volumes
Summary of plan metrics
| Comparison of techniques | ΔMU/Gy in % | ΔT in % | ΔCI in % | |
|---|---|---|---|---|
| 1 | V2C15 vs. V1C15 | −9,0 ± 2,3 | −24,4 ± 12,4 | −4,2 ± 3,9 |
| 2 | V2C15 vs. 2V1C15 | −4,9 ± 2,8 | 4,4 ± 13,0 | −3,0 ± 2,7 |
| 3 | V2C15 vs. V2C15_Part | −3,4 ± 2,3 | −15,9 ± 16,2 | −2,4 ± 3,7 |
| 4 | V2C15 vs. V2C40 | −1,8 ± 4,2 | 7,4 ± 23,8 | −0,5 ± 1,3 |
| 5 | V2C15 vs. V2C60 | −0,3 ± 3,4 | 61,5 ± 63,8 | −1,7 ± 2,1 |
| 6 | V2C15 vs. 2V1C15_60 | −1,5 ± 3,2 | 5,0 ± 35,5 | −0,4 ± 2,1 |
| 7 | V2C15 vs. 2V1C15_345 | −1,5 ± 2,9 | 29,2 ± 12,0 | −1,5 ± 2,5 |
Techniques with different beam configurations were compared with regard to plan metrics. The deviation of monitor units (MU), delivery time (T) and Paddick Conformity Index (CI) were calculated between each plan version and the reference plan (V2C15). For all patients, the mean and standard deviation are shown for comparisons #1–7
Fig. 3Comparison of the scoring method and COV method. The correlation of p-values derived from Wilcoxon test is plotted in logarithmic scaling. Significance level (dashed line) and corresponding quadrants are shown